Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

NCT01955460 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma
Stage III Cutaneous Melanoma AJCC v7
Stage IIIA Cutaneous Melanoma AJCC v7
Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions

BIOLOGICAL: Aldesleukin
DRUG: Cyclophosphamide
DRUG: Fludarabine Phosphate
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: NGFR-transduced Autologous T Lymphocytes
BIOLOGICAL: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]